Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?

Barresi,Valeria; Lucianò,Roberta; Vitarelli,Enrica; Labate,Agata; Tuccari,Giovanni; Barresi,Gaetano

doi:10.3892/ol.2010.191

Neutrophil gelatinase-associated lipocalin immunoexpression in colorectal carcinoma: A stage-specific prognostic factor?

Authors:
- Valeria Barresi
- Roberta Lucianò
- Enrica Vitarelli
- Agata Labate
- Giovanni Tuccari
- Gaetano Barresi
View Affiliations

Affiliations: Department of Human Pathology, University of Messina, 98125 Messina, Italy
Published online on: September 23, 2010 https://doi.org/10.3892/ol.2010.191
Pages: 1089-1096

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TNM post-surgical staging is considered to be one of the most powerful prognosticators for colorectal carcinoma. Although patient survival mostly decreases concomitantly to stage increase, in a percentage of cases TNM stage appears only to express the anatomic extent of the neoplasia with no correlation with clinical outcome. Thus, the identification of additional prognostic markers for colorectal cancer is required. Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that appears to play an important role in colorectal cancer progression. In order to evaluate whether NGAL expression may be considered as a predictor of colorectal cancer progression, we analyzed its correlation with clinicopathological characteristics, as well as with patient progression-free survival in a series of surgically resected colorectal carcinomas. A variable NGAL immunoexpression was found in 24 out of the 64 analyzed cases. When only the positive cases were considered, a significant association was found between a high NGAL expression and the presence of distant metastases or high tumor stage. In addition, the presence of NGAL was a significant negative prognostic marker correlated with a shorter progression-free survival in stage I colorectal carcinoma, but not in the remaining TNM stages. If our findings are confirmed in more extensive analyses on stage I colorectal carcinoma, NGAL assessment may be used in order to select those patients with a higher progression risk and to submit them to adjuvant therapies useful to prevent adverse outcome.

View Figures

View References

1	Landis H, Murray T, Bolden S and Wingo PA: Cancer statistics. Cancer J Clin. 49:8–31. 1999.
2	Wiggers T, Arends JW, Schutter B, Volovics L and Bosman FT: A multivariate analysis of pathologic prognostic indicators in large bowel cancer. Cancer. 61:386–389. 1988. View Article : Google Scholar : PubMed/NCBI
3	Wu XC, Chen VW, Steele B, Ruiz B, Fulton J, Liu L, Carozza SE and Greenlee R: Subsite-specific incidence rate and stage of disease in colorectal cancer by race, gender, and age group. Cancer. 92:2547–2554. 2001. View Article : Google Scholar : PubMed/NCBI
4	Di Gregorio C, Benfatti P, Losi L, Roncucci L, Rossi G, Ponti G, Marino M, Pedroni M, Scarselli A, Roncari B and Ponz de Leon M: Incidence and survival of patients with Dukes’ A (stages T1 and T2) colorectal carcinoma: a 15-year population-based study. Int J Colorectal Dis. 20:147–154. 2005.
5	Cowland JB and Borregaard N: Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics. 45:17–23. 1997. View Article : Google Scholar : PubMed/NCBI
6	Bratt T: Lipocalins and cancer. Biochim Biophys Acta. 1482:318–326. 2000. View Article : Google Scholar : PubMed/NCBI
7	Yang J, Goetz D, Li JY, Wang W, Mori K and Setlik D: An iron delivery pathway mediated by a lipocalin. Mol Cell. 10:1045–1056. 2002. View Article : Google Scholar : PubMed/NCBI
8	Goetz DH, Willie ST, Arme RS, Bratt T, Borregaard N and Strong RK: Ligand preference inferred from the structure of neutrophil gelatinase associated lipocalin. Biochemistry. 39:1935–1941. 2000. View Article : Google Scholar : PubMed/NCBI
9	Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN and Strong RK: The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 10:1033–1043. 2002. View Article : Google Scholar : PubMed/NCBI
10	Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J and Cantley LG: Expression of neutrophil associated-gelatinase lipocalin regulates epithelial morphogenesis in vitro. J Biol Chem. 280:7875–7882. 2005. View Article : Google Scholar : PubMed/NCBI
11	Bolignano D, Donato V, Lacquaniti A, et al: Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: a new protein enters the scene. Cancer Lett. 288:10–16. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hannai J, Mammoto T, Seth P, Mori K, Karumanchi SA, Barasch J and Sukhatme VP: Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem. 280:3641–3647. 2005.PubMed/NCBI
13	Bauer M, Eickhoff JC, Gould MN, Mundhenke C, Maas N and Friedl A: Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat. 108:389–397. 2008. View Article : Google Scholar : PubMed/NCBI
14	Iannetti A, Pacifico F, Acquaviva R, et al: The neutrophil gelatinase-associated lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor for thyroid neoplastic cells. Proc Natl Acad Sci USA. 105:14058–14063. 2008. View Article : Google Scholar : PubMed/NCBI
15	Barresi V, Ieni A, Bolignano D, Magno C, Buemi M and Barresi G: Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep. 24:305–310. 2010. View Article : Google Scholar
16	Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M and Kjeldsen L: Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut. 38:414–420. 1996. View Article : Google Scholar : PubMed/NCBI
17	Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang GG, Wang OC, Guo GL, Yang GY and Hu XQ: Clinical significance of Neutrophil gelatinase-associated lipocalin (NGAL) expression in primary rectal cancer. BMC Cancer. 91:342009.PubMed/NCBI
18	Hu L, Hittelman W, Lu T, Ji P, Arlinghaus R, Shmulevich I, Hamilton SR and Zhang W: NGAL decreases E-cadherin-mediated cell-cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest. 89:531–548. 2009. View Article : Google Scholar : PubMed/NCBI
19	Friedl A, Stoesz SP, Buckley P and Gould MN: Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 31:433–441. 1999. View Article : Google Scholar : PubMed/NCBI
20	Moniaux N, Chakraborty S, Yalniz M, et al: Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 98:1540–1547. 2008. View Article : Google Scholar
21	Kubben FJ, Sier CF, Hawinkels LJ, et al: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 43:1869–1876. 2007. View Article : Google Scholar : PubMed/NCBI
22	Zhang H, Xu L, Xiao D, et al: Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol. 60:555–561. 2007. View Article : Google Scholar
23	Devireddy LR, Gazin C, Zhu X and Green MR: A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 23:1293–1305. 2005. View Article : Google Scholar : PubMed/NCBI
24	Toyokuni S: Role of iron in carcinogenesis: cancer as a ferrotoxic disease. Cancer Sci. 100:9–16. 2009. View Article : Google Scholar : PubMed/NCBI
25	Le NTV and Richardson DN: The role of iron in cell cycle progression and the proliferation of neoplastic cells. Biochim Biophys Acta. 1603:31462002.
26	Fernandez CA, Yan L, Louis G, Yang J, Kutok JL and Moses MA: The matrix metallo-proteinase-9/neutrophil gelatinase associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res. 11:5390–5395. 2005. View Article : Google Scholar
27	Lee S, Jilani SM, Nikolova GV, Carpizo D and Iruela-Arispe M: Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol. 169:681–691. 2005. View Article : Google Scholar : PubMed/NCBI
28	Yan L, Borregaard N, Kjeldsen L and Moses MA: The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem. 276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
29	Leng X, Ding T, Lin H, et al: Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 69:8579–8784. 2009. View Article : Google Scholar : PubMed/NCBI
30	Buss JL, Greene BT, Turner J, Torti FM and Torti SV: Iron chelators in cancer chemotherapy. Curr Top Med Chem. 4:1623–1635. 2004. View Article : Google Scholar
31	Jones DT, Trowbridge IS and Harris AL: Effects of transferrin receptor blockade on cancer cell proliferation and hypoxia-inducible factor function and their differential regulation by ascorbate. Cancer Res. 66:2749–2756. 2006. View Article : Google Scholar : PubMed/NCBI